GSTM1 and colorectal cancer: Recent publications on the dynamics of Hb and iron parameters after intravenous iron treatment in patients with colorectal cancer with IDA suggest that repeat treatment may be needed, as a substantial proportion of the patients relapse to IDA 4–8 weeks after treatment [31, 32].